tiprankstipranks

Satellos Bioscience to Present Phase 1 Data for SAT-3247 at MDA Conference

Story Highlights
Satellos Bioscience to Present Phase 1 Data for SAT-3247 at MDA Conference

Confident Investing Starts Here:

An update from Satellos Bioscience ( (TSE:MSCL) ) is now available.

Satellos Bioscience announced it will present its first-ever Phase 1 safety and pharmacokinetic data for SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. This presentation marks a significant milestone for Satellos, highlighting the potential of SAT-3247 as a novel treatment for Duchenne muscular dystrophy and its continued progress in clinical trials, which may enhance its position in the biotech industry.

More about Satellos Bioscience

Satellos Bioscience Inc. is a public biotechnology company focused on developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The company is advancing its proprietary oral drug, SAT-3247, aimed at regenerating skeletal muscle in conditions such as Duchenne muscular dystrophy, independent of dystrophin and exon mutation status.

YTD Price Performance: -15.53%

Average Trading Volume: 166,300

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $78.85M

Learn more about MSCL stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App